Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci.
Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.
Jones
Ronald N
RN
JMI Laboratories, Inc., North Liberty, IA 52317, USA.
Fritsche
Thomas R
TR
Sader
Helio S
HS
Ross
James E
JE
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000494:pharmacology*; D004224:Diterpenes / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011083:Polycyclic Compounds; D013211:Staphylococcus aureus / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D000097567:Pleuromutilins
D000900:Anti-Bacterial Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004224:Diterpenes; D011083:Polycyclic Compounds; D000097567:Pleuromutilins; C508887:retapamulin